Cancers | Free Full-Text | KRAS in NSCLC: State of the Art and Future Perspectives
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein | PNAS
Targeted Therapies Are Game Changers for Lung Cancer Patients with a KRAS Mutation | Fox Chase Cancer Center - Philadelphia PA
KRAS Biomarker | Colorectal Cancer Alliance
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - eBioMedicine
Targeting Mutant KRAS for Immunogenic Cell Death Induction: Trends in Pharmacological Sciences
Small molecule combats cancer-causing KRAS protein at last
The current state of the art and future trends in RAS-targeted cancer therapies | Nature Reviews Clinical Oncology
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Frontiers | Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
Cancers | Free Full-Text | Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors | PNAS
KRAS: feeding pancreatic cancer proliferation: Trends in Biochemical Sciences
Cancers | Free Full-Text | KRAS G12C Mutations in NSCLC: From Target to Resistance
Vintage KRAS BRNO Narodni Podnik Czechoslovakian Army Visor Hat SZ 57 NICE SHAPE | eBay
Partnership seeks to develop KRAS degraders for cancer therapy | Frederick National Laboratory
Targeted Therapy for 'Undruggable' Lung Cancer Stems from Decades of UCSF Research | UC San Francisco
Partnership seeks to develop KRAS degraders for cancer therapy | Frederick National Laboratory
KRAS inhibitors, approved | Nature Cancer
Frontiers | Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Cureus | KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer | Article
KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib - Lacasta‐Plasin - 2021 - Clinical Genetics - Wiley Online Library
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling | Circulation Research
Frontiers | The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
